ONS PEP 2023 Evidence Update:

Chemotherapy-Induced Diarrhea, Immunotherapy-Induced Diarrhea,

and Radiation-Induced Diarrhea

Search Strategy

Databases searched: PubMed, CINAHL, Cochrane Library

- PubMed search performed 3/23/23, updated 6/14/23
 - (("Diarrhea/chemically induced"[Mesh] OR "Diarrhea/diet therapy"[Mesh] OR "Diarrhea/drug therapy"[Mesh] OR "Diarrhea/nursing"[Mesh] OR "Diarrhea/prevention and control"[Mesh] OR "Diarrhea/radiotherapy"[Mesh] OR "Diarrhea/therapy"[Mesh]) AND (Neoplasms[mh] OR neoplasm OR cancer OR oncolog* OR chemotherapy)) AND (("2016/05/01"[Date Create] : "3000"[Date Create]))
- CINAHL search performed 3/23/2023, updated 6/14/23
 - Search Modes and Expanders: Boolean/Phrase, Apply equivalent subjects
 - (MM Diarrhea OR TI (diarrhea* OR diarrhoea*) OR AB (diarrhea* OR diarrhoea*)) AND (MH Neoplasms OR neoplasm OR oncolog* OR chemotherapy) AND EM 201605-
- Cochrane Library searches performed 4/5/23, updated 6/14/23
 - Cochrane Trials
 - #1 MeSH descriptor: [Diarrhea] explode all trees and with qualifier(s): [chemically induced CI, diet therapy - DH, drug therapy - DT, nursing - NU, prevention & control - PC, radiotherapy - RT, therapy - TH]
 - #2 [mh Neoplasms] OR neoplasm OR cancer OR oncolog* OR chemotherapy
 - #3 #1 AND #2 with Publication Year from 2016 to 2023, in Trials (Word variations have been searched)
 - Cochrane Reviews
 - #1 MeSH descriptor: [Diarrhea] explode all trees and with qualifier(s): [chemically induced CI, diet therapy - DH, drug therapy - DT, nursing - NU, prevention & control - PC, radiotherapy - RT, therapy - TH]
 - #2 [mh Neoplasms] OR neoplasm OR cancer OR oncolog* OR chemotherapy
 - #3 #1 AND #2 with Cochrane Library publication date from May 2016 to Dec 2023, in Cochrane Reviews (Word variations have been searched.)

Supplementary searches for immunotherapy-induced diarrhea performed 6/14/2023

- PubMed
 - ("Colitis/chemically induced"[mh] OR "Colitis/drug therapy"[mh] OR "Colitis, Microscopic/drug therapy"[mh] OR colitis[tiab]) AND ("Immune Checkpoint Inhibitors"[mh] OR "immune checkpoint inhibitor*"[tw] OR "Programmed Cell Death 1 Receptor"[mh] OR "Programmed Cell Death 1 Receptor"[tw] OR "Programmed Cell Death Protein 1"[tw] OR "Programmed Cell Death 1 Protein"[tw] OR PD1[tw] OR "PD 1"[tw] OR "PD-1"[tw] OR PDL1[tw] OR "PDL 1"[tw] OR "PDL-1"[tw] OR "PD-L1"[tw] OR "CTLA-4 Antigen"[mh] OR "CTLA-4"[tw] OR "CTLA 4"[tw] OR "Cytotoxic T-Lymphocyte Associated Antigen 4"[tw] OR "Cytotoxic T Lymphocyte Antigen 4"[tw] OR "immune-mediated"[tw] OR "immune

mediated"[tw] OR "immune-related"[tw] OR "immune related"[tw] OR "checkpoint inhibitormediated"[tw] OR "checkpoint inhibitor mediated"[tw] OR "checkpoint inhibitor-related"[tw] OR "checkpoint inhibitor related"[tw] OR "checkpoint inhibitor-induced"[tw] OR "checkpoint inhibitor induced"[tw]) AND ("2016/05/01"[Date - Create] : "3000"[Date - Create])

• CINAHL

- Search Modes and Expanders: Boolean/Phrase, Apply equivalent subjects
- (MH "Colitis/CI/DT/DH/NU/PC/TH" OR TI colitis OR AB colitis) AND (MH "Immune Checkpoint Inhibitors+" OR "immune checkpoint inhibitor*" OR MH "Programmed Cell Death 1 Receptor" OR "Programmed Cell Death 1 Receptor" OR "Programmed Cell Death Protein 1" OR "Programmed Cell Death 1 Protein" OR PD1 OR "PD 1" OR "PD-1" OR PDL1 OR "PDL 1" OR "PDL-1" OR "PD-L1" OR "CTLA-4" OR "CTLA 4" OR "Cytotoxic T-Lymphocyte-Associated Antigen 4" OR "Cytotoxic T Lymphocyte Associated Antigen 4" OR "Cytotoxic T-Lymphocyte Antigen 4" OR "Cytotoxic T Lymphocyte Antigen 4" OR "immune-mediated" OR "immune mediated" OR "immune-related" OR "immune related" OR "checkpoint inhibitor-mediated" OR "checkpoint inhibitor mediated" OR "checkpoint inhibitor-related" OR "checkpoint inhibitor related" OR "checkpoint inhibitor-induced" OR "checkpoint inhibitor induced") AND EM 201605-
- Cochrane Library (Reviews and Trials databases, with word variations, 2016 to 2023)
 - ([mh Colitis/CI,DT] OR [mh "Colitis, Microscopic"/DT] OR colitis:ti,ab) AND ([mh "Immune Checkpoint Inhibitors"] OR "immune checkpoint inhibitor" OR "immune checkpoint inhibitors" OR [mh "Programmed Cell Death 1 Receptor"] OR "Programmed Cell Death 1 Receptor" OR "Programmed Cell Death Protein 1" OR "Programmed Cell Death 1 Protein" OR PD1 OR "PD 1" OR "PD-1" OR PDL1 OR "PDL 1" OR "PDL-1" OR "PD-L1" OR [mh "CTLA-4 Antigen"] OR "CTLA-4" OR "CTLA 4" OR "Cytotoxic T-Lymphocyte-Associated Antigen 4" OR "Cytotoxic T Lymphocyte Associated Antigen 4" OR "Cytotoxic T-Lymphocyte Antigen 4" OR "Cytotoxic T Lymphocyte Antigen 4" OR "immunemediated" OR "immune-related" OR "immune related" OR "checkpoint inhibitor-mediated" OR "checkpoint inhibitor mediated" OR "checkpoint inhibitor-related" OR "checkpoint inhibitor related" OR

Updated Inclusion & Exclusion Criteria for 2023


Inclusion Criteria:

- 1. Full research report, systematic review, clinical guidelines, or meta-analysis
- 2. Study that reports result of measurement of chemotherapy-, radiotherapy-, or immunotherapy-induced diarrhea
- 3. The study examines an intervention aimed at affecting diarrhea.
- 4. Study sample must include patients with cancer
- 5. Sample size of at least 40 or 20 per study group
- 6. For complex interventions, the description of the intervention must be sufficient to identify the components of that intervention

Exclusion Criteria:

- 1. Grey literature
- 2. Descriptive studies
- 3. Studies involving the management of postoperative diarrhea or patients with ostomies

PRISMA Diagram



Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... McKenzie, J. E. (2021). PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. *BMJ 372*, n160. <u>https://doi.org/10.1136/bmj.n160</u>